Dr. Mike Reed to Participate in Roundtable Panel of American Society of Phamacometrics
Industry Presenters Will Focus on the Use and Benefits of Physiologic, Mechanistic Models in Drug Development
San Carlos, CA, January 30, 2012 --(PR.com)-- Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that Mike Reed, PhD, Vice President of Client Services, will participate in a roundtable panel to discuss "The Use of Physiological, Mechanistic Models in Drug Development and Therapy: Introduction, Case Studies, Impact, and Ideas for Applications." This is a local event sponsored by the American Society of Pharmacometrics (ASoP), to be held on Thursday, February 2, 2012, in Bridgewater, New Jersey. At this roundtable, industry experts will summarize the benefits and challenges in using physiological models for drug development, describe the modeling approaches used, report on program outcomes, and share ideas for the future of modeling. Registration for the event can be found at http://www.go-asop.org/physiological-models-N.
About Rosa
Rosa informs our customer’s most critical decisions – from preclinical through clinical development – with the creation and use of mathematical models that simulate disease physiology, drug action, patient variability, and trial outcomes. To address the full spectrum of related issues, Rosa offers two customized approaches: classic pharmacokinetic/ pharmacodynamic (PK/PD) models and Rosa’s innovative PhysioPD™ models. With these approaches, Rosa’s clients collaborate in model creation and testing, retain the final model, and acquire the ability to use it and understand its implications for their drug development programs. Rosa’s staff have unparalleled professional experience in using drug-disease modeling and simulation (M&S) to accelerate drug development and have completed hundreds of engagements with dozens of clients in multiple therapeutic areas. The Rosa team is unique in their breadth and depth of disease area experience, which includes metabolic and cardiovascular diseases, oncology, gastro-intestinal disease, inflammatory diseases, immune dysfunction (including rheumatoid arthritis), pain, skin conditions, respiratory disorders, and antibacterials/antivirals. For more information, visit www.rosaandco.com.
Rosa and the Rosa logo are registered trademarks of Rosa & Co. LLC.
###
About Rosa
Rosa informs our customer’s most critical decisions – from preclinical through clinical development – with the creation and use of mathematical models that simulate disease physiology, drug action, patient variability, and trial outcomes. To address the full spectrum of related issues, Rosa offers two customized approaches: classic pharmacokinetic/ pharmacodynamic (PK/PD) models and Rosa’s innovative PhysioPD™ models. With these approaches, Rosa’s clients collaborate in model creation and testing, retain the final model, and acquire the ability to use it and understand its implications for their drug development programs. Rosa’s staff have unparalleled professional experience in using drug-disease modeling and simulation (M&S) to accelerate drug development and have completed hundreds of engagements with dozens of clients in multiple therapeutic areas. The Rosa team is unique in their breadth and depth of disease area experience, which includes metabolic and cardiovascular diseases, oncology, gastro-intestinal disease, inflammatory diseases, immune dysfunction (including rheumatoid arthritis), pain, skin conditions, respiratory disorders, and antibacterials/antivirals. For more information, visit www.rosaandco.com.
Rosa and the Rosa logo are registered trademarks of Rosa & Co. LLC.
###
Contact
Rosa & Co LLC
Rebecca Baillie
530-661-7476
www.rosaandco.com
Rebecca Baillie
530-661-7476
www.rosaandco.com
Contact
Categories